Background. Cisplatin is a potent chemotherapeutic drug whose nephrotoxic effect is a major complication and a dose-limiting factor for antitumoral therapy. There is much evidence that inflammation contributes to the pathogenesis of cisplatin-induced nephrotoxicity. We found that cilastatin, a renal dehydropeptidase-I inhibitor, has protective effects in vitro and in vivo against cisplatin-induced renal damage by inhibiting apoptosis and oxidation. Here, we investigated the potential use of cilastatin to protect against cisplatin-induced kidney injury and inflammation in rats. Methods. Male Wistar rats were divided into four groups: control, cilastatin-control, cisplatin and cilastatin-cisplatin. Nephrotoxicity was assessed 5 days after administration of cisplatin based on blood urea nitrogen, creatinine, glomerular filtration rate (GFR), kidney injury molecule (KIM)-1 and renal morphology. Inflammation was measured using the electrophoretic mobility shift assay, immunohistochemical studies and evaluation of inflammatory mediators. Results. Compared with the control rats, cisplatin-administered rats were affected by significant proximal tubule damage, decreased GFR, increased production of inflammatory mediators and elevations in urea, creatinine and tissue KIM-1 levels. Cilastatin prevented these changes in renal function and ameliorated histological damage in cisplatin-administered animals. Cilastatin also reduced pro-inflammatory cytokine levels, activation of nuclear factor-jB and CD68-positive cell concentrations. Conclusions. Cilastatin reduces cisplatin-induced nephrotoxicity, which is associated with decreased inflammation in vivo. Although the exact role of decreased inflammation in nephroprotection has not been fully elucidated, treatment with cilastatin could be a novel strategy for the prevention of cisplatininduced acute kidney injury.
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I N T R O D U C T I O N
Cisplatin (cis-diamminedichloroplatinum II) is a potent antineoplastic agent that is widely used to treat various types of tumors [1, 2] . However, its clinical application is limited by the development of time-and dose-dependent nephrotoxicity, which affects about one-third of patients receiving high-dose cisplatin [3, 4] .
Although the mechanisms underlying cisplatin-induced nephrotoxicity are not fully understood, apoptosis, oxidative stress and inflammation are reported to be involved in the development and amplification of kidney injury [1, 5, 6] . Recent studies highlight the role of inflammation in this process, with activation of tumor necrosis factor a (TNFa) and nuclear factor-jB (NF-jB) considered to play a decisive role by inducing a variety of signaling pathways, leading to pro-inflammatory cytokine and chemokine production and cell infiltration, which exacerbates kidney injury [7] [8] [9] [10] [11] . In fact, inhibition or prevention of the activity of these molecules is associated with improvement of cisplatin-induced kidney injury [11] [12] [13] . Therefore, the search for new molecules that modulate renal inflammation is an important research area that may lead to therapies to prevent cisplatin-induced kidney injury.
Cilastatin is a specific inhibitor of renal dehydropeptidase-I (DHP-I), which is located on epithelial brush-border cholesterol lipid rafts [14] . It was initially designed to inhibit hydrolysis and uptake of the antibiotic imipenem, thus enabling it to be less toxic and more easily eliminated through urine [15, 16] . However, older clinical studies support the protective role of cilastatin (imipenem-cilastatin) against cyclosporin (CsA)-induced nephrotoxicity [17] [18] [19] , and recent experimental evidence from our group indicates that cilastatin protects proximal 
tubular epithelial cells from toxic apoptotic and oxidative damage induced by cisplatin both in vitro and in vivo, with no reduction in the effect of cisplatin on cancer cells [20] [21] [22] [23] .
The aim of this study was to evaluate the effects of cilastatin on cisplatin-induced renal inflammation and assess the protective effects of cilastatin against cisplatin-induced nephrotoxicity in a rat model. Our findings could have important implications for the prevention of cisplatin-induced nephrotoxicity and for the treatment of other inflammatory kidney diseases.
M A T E R I A L S A N D M E T H O D S

Animals and drug treatment
Male Wistar rats (Charles River, Wilmington, MA, USA) were housed in a humidity-and temperature-controlled environment with a 12-h light-dark cycle and allowed free access to food and water. The animals were weighed at the beginning of the experiment and immediately before being euthanized. All the procedures were approved by the Ethics Committee on Animal Experimentation from the Hospital Gregorio Marañ on, Madrid, Spain, and animals were cared for in accordance with Directive 2010/63/EU and Spanish Royal Decree 53/2013 on the protection of animals used for experimentation and other scientific purposes.
At the start of the experiments, the rats were 7 weeks of age and weighed 250-270 g. Animals were divided into four groups: untreated control rats (n ¼ 7); cilastatin-treated rats (n ¼ 7); cisplatin-injected rats (n ¼ 8); and cilastatin-treated, cisplatininjected rats (n ¼ 8). Cisplatin 5 mg/kg (Pharmacia Nostrum S.A., Barcelona, Spain) or its vehicle (0.9% saline serum) was administered by a single intraperitoneal injection to all rats in the same manner and volume (1 mL/100 g). Cilastatin 75 mg/kg (Merck Sharp and Dohme S.A., Madrid, Spain) was injected intraperitoneally twice daily (0.25 mL/100 g) from the first day cisplatin was administered until the end of the experiment. The first dose was started immediately before administration of cisplatin. Cilastatin was substituted by vehicle (0.9% saline solution) in the other groups.
The dose and administration period of cisplatin were selected based on the proven effectiveness of the drug in inducing nephrotoxicity [12, 21, 24, 25] . The dose of cilastatin was selected based on previous studies by our group [21] [22] [23] and considering earlier evaluations which showed that imipenem/ cilastatin reduced CsA-induced nephrotoxicity [26, 27] .
On the fifth day after cisplatin or saline injection, the animals were euthanized and samples collected (see Supplementary data for further details).
Analysis of renal function
Serum and urine levels of creatinine and blood urea nitrogen (BUN) were measured automatically in a Dimension RxL autoanalyzer (Dade-Behring, Siemens, Eschborn, Germany). The glomerular filtration rate (GFR) was calculated, as was the 
Histology
Paraffin-embedded renal sections (4-mm thick) were stained with periodic acid-Schiff (PAS). Renal tubular damage (see Supplementary data) in PAS sections was scored using a previously described semiquantitative scale [21, 28] .
Analysis of transcription factor activity NF-jB activity was evaluated by binding 70 mg of protein extracts from renal tissue with an oligonucleotide consensus sequence labeled with c-[ 32 P]ATP, and the complexes formed were analyzed using electrophoretic mobility shift assay (EMSA). Nuclear protein extraction and EMSA were performed as previously described [29] .
Western blot analysis
Western blot analysis was performed as previously described [20, 30] . The antibodies used are detailed in Supplementary data.
Immunohistochemistry
Immunohistochemistry was carried out as previously described [21, 28] . The antibodies used are detailed in Supplementary data.
Real-time polymerase chain reaction
Total RNA was isolated from kidney homogenate using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. Two micrograms of total RNA were reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Target gene expression (the primers used are found in Supplementary data) was quantified 
. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the housekeeping gene and was amplified in parallel with the genes of interest. The D threshold cycle (DCT) technique was applied for the quantitative cDNA analysis [28] . Statistical analyses were carried out for at least six to eight replicate experimental samples in each set. All the measurements were performed in duplicate. Results for double-distilled water controls were negative in all the runs.
Serum myeloperoxidase
Myeloperoxidase (MPO) activity was measured in serum using the MPO Colorimetric Activity Assay Kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer's instructions.
Measurement of serum cytokines
Serum TNFa and interleukin-6 (IL-6) were measured using the Rat TNFa ELISA Kit (Thermo Fisher Scientific, Waltham, MA, USA) and Rat IL-6 ELISA Kit (Gene Probe, Diaclone, Besançon, France), respectively, according to the manufacturer's instructions.
Serum monocyte chemoattractant protein (MCP-1) and transforming growth factor b (TGFb) were measured using microbeadbased assays developed and validated in J.V.B.'s laboratory (see Supplementary data for further details) [31] .
Measurement of cytokines in urine
MCP-1, IL-6, IL-10 and TGFb levels were measured in urine using microbead-based assays developed and validated in J.V.B.'s laboratory (see Supplementary data for further details) [31] .
Statistical analysis
Quantitative variables were summarized as the mean 6 standard error of the mean (SEM). Equality of variances was tested using Levene's test. Normally distributed continuous variables were analyzed using analysis of variance (ANOVA), with the least significant difference test as a post hoc approach test to determine specific group differences. Differences were considered statistically significant if bilateral a-values were <0.05. Tests were performed using Statistical Package for Social Sciences (SPSS) version 11.5 (SPSS, Chicago, IL, USA).
R E S U L T S
Cilastatin ameliorates cisplatin-induced kidney injury in rats
The administration of cisplatin increased serum creatinine and BUN and decreased values of GFR in the test groups, compared with the control groups ( Figure 1A-C) . Treatment with cilastatin significantly reduced the effects of cisplatin for both parameters. Moreover, cilastatin was able to reduce the renal hypertrophy induced by cisplatin ( Figure 1D ). Cilastatin alone did not produce changes for any of the parameters in the test groups compared with the control groups.
The acute kidney injury (AKI) biomarker kidney injury molecule (KIM)-1 was measured to confirm the nephrotoxic effect of cisplatin ( Figure 2 ). Cilastatin alone had no effects on renal KIM-1 expression. KIM-1 levels were significantly increased in relation to serum creatinine and BUN at both the mRNA level ( Figure 2H) and at the protein level (Figure 2A -G) after administration of cisplatin. Cilastatin reduced protein expression compared with control levels, although while gene expression was reduced, it did not reach statistical significance (Figure 2 ).
Cilastatin attenuates cisplatin-induced morphological tubular damage
Histological examination revealed blebbing of apical membranes, epithelial necrosis, protein casts formation, vacuolization and presence of mitotic nuclei in the proximal tubules of the cisplatin-administered group (Figure 3A-D) . Treatment with cilastatin significantly improved cisplatin-induced tubular damage, as shown in the semiquantitative tubular damage score ( Figure  3E ). Cilastatin alone had no effects on tubular morphology in comparison with the control groups ( Figure 3A , C and E). Compared with control groups, the pro-inflammatory effect of cisplatin was associated with activation of NF-jB in the kidneys ( Figure 4A ). Cilastatin significantly decreased cisplatininduced NF-jB activity, as shown by the semiquantitative NFjB activity score ( Figure 4B ).
Effects of cisplatin and cilastatin on urine and serum cytokines NF-jB regulates the expression of many cytokines that participate in inflammatory processes. Figure 5 shows that administration of cisplatin increases the concentration of MCP-1 and IL-6 both in serum and in urine. Furthermore, cisplatinadministered rats have increased concentrations of TNFa in serum and decreased levels of IL-10 in urine. Treatment with cilastatin partially or totally restored the urinary and serum cytokine levels compared with the controls (Figure 5 ). Cilastatin alone had no effects on urine and serum cytokine concentration compared with the control groups.
Cilastatin ameliorates cisplatin-induced inflammatory cell infiltration
The immunohistochemical studies revealed that recruitment of monocytes/macrophages (as evidenced by labeling with CD68) in the renal cortices and outer medulla of cisplatinadministered rats was more intense than in controls. This finding was consistent with elevated MCP-1 levels ( Figure 6A-E) . Cilastatin-treated rats had fewer CD68-positive cells than the cisplatin-administered group ( Figure 6B, D and E) .
Moreover, cisplatin significantly increased systemic neutrophil activation (evidenced by increased MPO activity), which was partially attenuated by cilastatin ( Figure 6F ). Cilastatin alone had no effects on CD68-positive cells or systemic MPO activity when compared with vehicle-treated control groups ( Figure 6F ).
Effects of cisplatin and cilastatin on expression of adhesion molecules in the kidneys
To further understand the ability of cilastatin to inhibit inflammatory cell infiltration into the injured kidney, we measured the mRNA expression of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 using quantitative RT-PCR. Figure 7F and G shows the relative expression of ICAM-1 and VCAM-1 normalized to GAPDH mRNA. The results revealed that administration of cisplatin increased the expression of both ICAM-1 and VCAM-1 compared with the control groups. Treatment with cilastatin significantly reduced cisplatin-induced changes. These results were confirmed by analysis of VCAM-1 protein levels using immunohistochemistry ( Figure 7A -E). Cisplatin-administered rats presented higher levels of VCAM-1 in renal tissue than the control groups. Treatment with cilastatin significantly reduced the frequency of cisplatin-induced effects. Cilastatin alone had no effects on ICAM-1 and VCAM-1 mRNA expression and the presence of VCAM-1 in renal tissue (Figure 7 ).
Cilastatin reduces cisplatin-induced increased expression of TGFb1
TGFb is a pro-inflammatory and profibrotic cytokine that exacerbates kidney damage. Immunohistochemistry revealed higher levels of TGFb1 in the renal tissue of cisplatin- Figure 8F and G) . In addition, TGFb1 mRNA expression was also higher after administration of cisplatin than in the control groups ( Figure 8H ). Treatment with cilastatin significantly decreased TGFb1 mRNA and protein levels in cisplatin-administered animals.
D I S C U S S I O N
An increased inflammatory response (together with oxidative stress and apoptosis) has been implicated in the development of cisplatin-induced AKI [1, 5, 6, 32] . Many studies have shown that induction of pro-inflammatory cytokines together with infiltration by macrophages and neutrophils, contributes to the pathogenesis and exacerbation of renal tissue damage in cisplatinadministered animals, resulting in a vicious cycle [1, 5, 12, [33] [34] [35] . Therefore, modulation of the renal inflammatory reaction may help to prevent cisplatin-induced AKI. Although several in vivo approaches have been proposed to reduce inflammation in cisplatin-induced nephrotoxicity, it is unclear whether such approaches limit the anticancer efficacy of cisplatin [1] .
Several cytokines (e.g. TNFa, IL-1b, MCP-1 and IL-6) are upregulated in the kidney in the inflammatory cascade triggered by cisplatin [1, 11, 32, 36] . TNFa plays a key role in the nephrotoxicity of cisplatin by inducing a variety of signaling pathways with cellular responses ranging from activation of inflammation to cell death [1, 11, 32, 37] . In fact, TNFa is able to activate other cytokines and/or chemokines such as ICAM-1 and MCP-1 [11, 36, 37] , in turn leading to activation of the NF-jB pathway [36, 38] . There is strong evidence for the pivotal role of NF-jB activation in the pathogenesis of cisplatin-induced renal inflammation [10, 34, 39] . NF-jB regulates neutrophil, macrophage and lymphocyte biology, as well as the synthesis of hundreds of proinflammatory genes (cytokines, growth factors and adhesion molecules), including TNFa, thus amplifying the kidney injury caused by inflammation.
Using pharmacological and genetic approaches, many authors have shown that inhibition of activation of TNFa and NFjB after administration of cisplatin was associated with reduced damage and improved kidney function and morphology [1, 7, 12, 13, 40] .
In the present study, we show for the first time that cilastatin reduces cisplatin-induced inflammation by attenuating of NFjB and synthesis of major pro-inflammatory cytokines including TNFa and the recruitment of the inflammatory cells into renal tissue. Thus, consistent with previous reports, we found that levels of serum TNFa and NF-jB in renal tissue are markedly increased in cisplatin-administered rats. However, we found that treatment with cilastatin results in a significant decrease in the levels in both molecules, leading to a reduction in inflammatory damage.
We also evaluated the expression of chemokines, interleukins and adhesion molecules with a known major role in the inflammatory process. ICAM-1 and VCAM-1 play an [32, 41] . Consistent with the results reported by other groups, we showed increased mRNA and/or protein levels of VCAM-1, ICAM-1 and MCP-1 in tissue, urine or serum in cisplatin-administered rats [36, [40] [41] [42] . Studies based on various strategies (D-Ribose, sulforaphane or anti-CD54) have shown that the decrease in levels of these molecules in cisplatin-administered animals improves kidney damage caused by inflammation [6, 36, 41] . Cilastatin inhibited the increase in these factors and consequently prevented infiltration of monocyte/macrophages into renal tissue and decreased neutrophil stimulation, as evidenced by inhibition of MPO activity at the systemic level. Macrophages and neutrophils intensify the cytotoxic effects of cisplatin, because they are reservoirs of pro-inflammatory cytokines, which they release together with reactive oxygen species (ROS) into damaged kidneys [6, 11, 40, 43] . Thus, inhibition of tissue infiltration by these cells can help to protect kidneys against cisplatininduced renal damage. Several studies have shown that cytokines such as IL-10 counterbalance or inhibit the increase in other pro-inflammatory cytokine levels in order to protect tissue against injury in various pathophysiological conditions. Tadagavadi and Reeves [44] showed increased inflammation in cisplatininduced renal damage in the absence of IL-10 by using IL-10-deficient mice. IL-10 exerts anti-inflammatory and anticytotoxic effect in kidney injury associated with lupus nephritis, immune complex glomerulonephritis and ischemic or cisplatin-induced nephrotoxicity [44, 45] . In our study, animals receiving both cisplatin and cilastatin maintained IL-10 levels similar to those of the control groups, whereas levels decreased in rats receiving only cisplatin, thus confirming findings reported elsewhere [44, 46] .
Fibrosis associated with inflammation has been also demonstrated in cisplatin-induced kidney injury [12, 47] . In particular, studies have demonstrated that cisplatin increases levels of the fibrogenic cytokine TGFb, which stimulates extracellular matrix protein production and deposition, leading to glomerulosclerosis and tubulointerstitial fibrosis [48] . In fact, Bayomi et al. [47] reported that inhibition of the TGFb receptor protects kidneys after administration of cisplatin by inhibition of apoptotic effects, pro-inflammatory cytokines and renal fibrosis markers. In the present study, we found that cisplatin-administered animals had elevated renal and systemic levels of TGFb, which were effectively suppressed by cilastatin. Cilastatin significantly decreased serum creatinine and BUN, and improved GFR and the morphologic and structural features that are characteristic of declining renal function. One such feature is the renal hypertrophy, an adaptive growth of kidney tissue to restore the lost renal function that finally leads to tubular atrophy and interstitial fibrosis [49] . Several studies have shown an increase in the kidney:body weight ratio after administration of cisplatin [24, 50] . Similarly, TGFb is also a major mediator of hypertrophic cellular changes in kidney diseases (see above), and it is known that anti-TGFb therapy attenuates renal hypertrophy, thus improving renal dysfunction [49, 51, 52] . Our results confirm these findings and the finding that treatment with cilastatin reduced levels of kidney interstitial immune cells and TGFb, which may have helped to decrease the renal hypertrophy previously induced by cisplatin.
Cilastatin also decreased levels of KIM-1, which were increased by administration of cisplatin. KIM-1 is a wellrecognized biomarker for kidney injury and is upregulated in the proximal tubule of the injured kidney [53] . Yang et al. [54] recently showed that KIM-1-mediated epithelial cell phagocytosis of apoptotic cells after administration of cisplatin or ischemia protects the kidney after acute injury by downregulating inflammation and, specifically, by decreasing NF-jB activity in a p85-dependent manner. In contrast, Nozaki et al. [55] showed that KIM-1 signaling helps activate T cells, which mediate cisplatin-induced AKI leading to increased leukocyte recruitment and inflammatory injury. The authors showed that the administration of anti-KIM-1 antibodies protected against renal damage by decreasing cisplatin-induced NF-jB activation [55] . In this study, we did not examine whether or not the role of cilastatin on KIM-1 function mediated injury or protection in cisplatinadministered kidneys, although the downregulation of renal KIM-1 expression observed in our model after treatment with cilastatin was associated with decreased NF-jB activation and improvement of kidney damage.
Our results show that cilastatin is able to decrease inflammation in cisplatin-induced nephrotoxicity and that is nephroprotective. However, Linkermann et al. [56] reported that cisplatin-induced kidney nephropathy is mediated through Fas ligand (FasL), concluding that cisplatin-induced kidney injury may be mediated through FasL expressed in tubular cells rather than inflammatory cells. In addition, several studies have shown [42, [57] [58] [59] [60] . We previously showed that cilastatin significantly decreased expression of FasR, FasL, cleaved caspase-8 and ROS, thereby decreasing cell death in the kidneys of the animals that received cisplatin [21] . Consequently, although our new results suggest a major cilastatin-induced nephroprotective effect against inflammation, we cannot assert that this effect is the cause or simply a consequence of decreasing apoptosis, oxidative stress and, ultimately, cell death. Additional experiments should be performed to establish the role of decreasing inflammation by cilastatin in the protection of cisplatin-induced kidney injury. Such knowledge is essential, as many other renal inflammatory conditions could benefit from the potential protective effects of cilastatin.
In conclusion, we provide evidence that cilastatin, a renal DHP-I inhibitor, decreases renal toxicity in cisplatin-induced kidney injury. The nephroprotective effect observed was associated with suppression of TNFa and NF-jB and the subsequent decreased inflammatory response. However, it remains to be determined whether this is the cause or a consequence of protection. Cilastatin could prove useful as an adjuvant in the treatment of cancer and protect against cisplatin-induced renal injury.
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